.png "Cytokinetics Inc (NASDAQ: CYTK)")
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics Inc (CYTK), with a price target of $26.00. The company’s shares closed last Monday at $11.57.
According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.4% and a 28.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Cytokinetics Inc has an analyst consensus of Strong Buy, with a price target consensus of $20.17.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.94 and a one-year low of $5.75. Currently, Cytokinetics Inc has an average volume of 420K.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYTK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
